Major Developments: Empowered by the "Shan Hai · Zhi Yi Large Model," CloudMinds (09678) secured a major regional medical cooperation order exceeding 200 million yuan. Kelun-Biotech B (06990) received Breakthrough Therapy Designation from the NMPA for its core product, the TROP2 ADC drug sacituzumab govitecan (SAC-TMT), combined with the immunotherapy pembrolizumab as a first-line treatment for PD-L1 positive locally advanced or metastatic non-small cell lung cancer. Insilico Medicine (03696) entered into a multi-year anti-tumor drug R&D collaboration with Servier valued at $888 million. HUTCHMED (00013) initiated the Phase III stage of its ongoing study evaluating surufatinib in combination with camrelizumab for the treatment of previously untreated pancreatic ductal adenocarcinoma. Ascletis Pharma-B (01672) announced that the IND for its 13-week Phase II study of ASC30 in diabetic subjects was approved by the US FDA. SISRAM MED (01696) announced that the re-authorized injectable Botulinum Toxin Type A has passed the quality standard inspection by the National Institutes for Food and Drug Control. CanSino Biologics (06185): The 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/Tetanus Toxoid) received clinical trial approval in China. Sihuan Pharmaceutical (02005): Obtained the drug production registration approval for Perindopril Amlodipine Tablets (III) (containing Perindopril Arginine 10mg and Amlodipine Besylate 5mg). Sunny Optical Technology (02382): Proposed spin-off of the Group's automotive-related optical business and its separate listing on the Main Board of The Stock Exchange of Hong Kong Limited. Dongyangguang Pharmaceutical (06887): HECN30227 has completed enrollment of the first subject in China. Haitian International (01882) subsidiary intends to sell 100% equity of Guohua Machinery for 342 million yuan. Yuexiu Property (00123) subsidiary intends to sell an aggregate 73.74% actual interest in Hangzhou Yueyun. CIMC (02039) subsidiary CIMC Logistek plans to introduce strategic investors through a capital increase and expansion, along with the transfer of a small number of existing shares. Operating Performance: Chifeng Jilong Gold (06693) issued a profit alert, expecting annual attributable net profit to be approximately 3.0 billion to 3.2 billion yuan, an increase of about 70% to 81% year-on-year. Wenzhou Kangning Hospital (02120) reported approximately 720,200 outpatient visits for 2025, a 29% year-on-year increase. SERES (09927) reported total vehicle sales of 63,700 units in December, an increase of 53.54% year-on-year. Concord New Energy (00182) reported equity generation of 790.32 GWh in December. Country Garden (02007) reported contracted sales attributable to shareholders' equity of approximately 2.69 billion yuan for December.